Sustained Drug Exposure Drives Efficacy in Mice: PK/PD Analysis of Corallopyronin A against Wolbachia using Physiologically Based Absorption Modeling.

Authors

J Heitkötter, F Risch, A Schiefer, K Pfarr, M P Hübner, S Kehraus, A Hoerauf, X Pepin, K G Wagner

Published in

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. Pages 107642. Aug 15, 2026. Epub Aug 15, 2026.

Abstract

Corallopyronin A (CorA) depletes essential Wolbachia endosymbionts of filarial nematodes and is therefore a promising candidate for treating the neglected tropical diseases lymphatic filariasis and onchocerciasis. To optimize anti-Wolbachia therapy, the pharmacokinetic/pharmacodynamic (PK/PD) relationship was investigated. Due to the intra-nematode and -cellular target, conventional minimal inhibitory concentration could not be determined. Instead, an iterative approach was used to define PD efficacy thresholds and compare them with IC₅₀/IC₉₀ values from infected cells. A physiologically based biopharmaceutics model (PBBM) was developed in GastroPlus®, incorporating physicochemical in vitro and in vivo parameters to predict PK in mice. A mechanistic dissolution model for a CorA-povidone suspension was implemented and verified with in vivo single dose PK data. Simulations provided trough and peak concentrations (C_max), AUC and time above threshold for multiple dosing regimens. In vivo efficacy was assessed in a Litomosoides sigmodontis mouse infection model by quantifying Wolbachia burden. CorA showed potent in vitro activity (IC₅₀/ IC₉₀: 0.007/0.030 µg/mL). In vivo, fractionated dosing improved efficacy. C_max poorly predicted treatment outcome, while trough concentration and AUC over iterative model dependent efficacy threshold correlated strongly with the Wolbachia reduction (R²: 0.89 and 0.81). These thresholds show strong concordance with the experimentally determined IC₅₀/IC₉₀ values. The duration of drug exposure above 2.25 µg/mL was the most accurate predictor of efficacy (R²: 0.93). Based on the PK/PD modeling, an effective mouse dose of 16 mg/kg BID was identified. These findings highlight the importance of sustained drug exposure for optimizing CorA regimens and will guide clinical development.

PMID:
42603636
Bibliographic data and abstract were imported from PubMed on 16 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.